Cardiac Toxicity After Radiotherapy for Stage III Non–Small-Cell Lung Cancer: Pooled Analysis of Dose-Escalation Trials Delivering 70 to 90 Gy

Wang, Kyle; J. Eblan, Michael; M. Deal, Allison; B. Lipner, Matthew; M. Zagar, Timothy; Wang, Yue; Mavroidis, Panayiotis; B. Lee, Carrie; C. Jensen, Brian; Rosenman, Julian; A. Socinski, Mark; E. Stinchcombe, Thomas; B. Marks, Lawrence

doi:10.1200/jco.2016.70.0229

Public

Cardiac Toxicity After Radiotherapy for Stage III Non–Small-Cell Lung Cancer: Pooled Analysis of Dose-Escalation Trials Delivering 70 to 90 Gy

Published in Journal of Clinical Oncology • Feb 23, 2017

Authors:

Kyle Wang

Michael J. Eblan

Allison M. Deal

Abstract

Purpose The significance of radiotherapy (RT) -associated cardiac injury for stage III non-small-cell lung cancer (NSCLC) is unclear, but higher heart doses were associated with worse overall survival in the Radiation Therapy Oncology Group (RTOG) 0617 study. We assessed the impact of heart dose in ...

Subject

Medicine

Internal medicine

Heart failure

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!